Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts Otsuka Pharmaceutical/Bristol-Myers Squibb's Abilify will garner 12% of the schizophrenia market in 2012 when it emerges as a first-choice therapy for treatment of the disease. The new Pharmacor study entitled Schizophrenia also reports that the schizophrenia market will face tough generic erosion after 2006.

"The impact of generics will be the greatest in the United States, where the market will experience a 4.7% annual decline during 2007-2012," said Michelle Grady, analyst at Decision Resources. "The launch of Abilify, novel formulations of atypical antipsychotics, and a few other less-promising emerging agents will be the only protection against a more precipitous decline."

Disease Facts - Schizophrenia

Schizophrenia is a chronic and debilitating psychiatric illness marked by severe disturbances in cognition, perception, and emotion. Virtually all patients require drug therapy to cope with the symptoms, but as many as 30% of schizophrenic patients are refractory to available drugs, and many who respond favorably to treatment endure serious side effects.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Schizophrenia is a Cognos study.

About Decision Resources

Decision Resources is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

PCPs and Cardiologists Anticipate the Benefits of Zetia/Zocar Combination for the Treatment of Dyslipidemia While HMOs are Resistant to its Addition to Formularies

View Now